Halozyme Therapeutics ROCE 2024

Halozyme Therapeutics Aktienanalyse

What does Halozyme Therapeutics do?

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Halozyme Therapeutics's Return on Capital Employed (ROCE)

Halozyme Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Halozyme Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Halozyme Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Halozyme Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Halozyme Therapeutics stock

What is the ROCE (Return on Capital Employed) of Halozyme Therapeutics this year?

The ROCE of Halozyme Therapeutics is 4.06 undefined this year.

How has the ROCE (Return on Capital Employed) of Halozyme Therapeutics developed compared to the previous year?

The ROCE of Halozyme Therapeutics has increased by 138.08% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Halozyme Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Halozyme Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Halozyme Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Halozyme Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Halozyme Therapeutics impact the company?

An increase in the ROCE of Halozyme Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Halozyme Therapeutics affect the company?

A decrease in ROCE of Halozyme Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Halozyme Therapeutics?

Some factors that can affect Halozyme Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Halozyme Therapeutics so important for investors?

The ROCE of Halozyme Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Halozyme Therapeutics take to improve the ROCE?

To improve the ROCE, Halozyme Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.